back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2025-10-23 16:09 Tx date 2025-10-16 |
$LSL
LSL Pharma Group Inc. |
Mokaddem, Noureddine
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
6,250,000 | ||
| Filed 2025-10-17 13:52 Tx date 2025-10-16 |
$LSL
LSL Pharma Group Inc. |
Mokaddem, Noureddine
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
6,250,000 | ||
| Filed 2025-09-02 17:12 Tx date 2025-08-29 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$87,500
+125,000 vol $0.70 each |
375,000 | |
| Filed 2025-09-02 17:11 Tx date 2025-08-29 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
16 - Acquisition or disposition under a prospectus exemption
|
$50,000
+125,000 vol $0.40 each |
375,000 | |
| Filed 2025-09-02 10:47 Tx date 2025-08-29 |
$LSL
LSL Pharma Group Inc. |
Roberge, François
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+187,500 vol |
259,000 | |
| Filed 2025-09-02 10:46 Tx date 2025-08-29 |
$LSL
LSL Pharma Group Inc. |
Roberge, François
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares catégorie A
16 - Acquisition or disposition under a prospectus exemption
|
$75,000
+187,500 vol $0.40 each |
4,935,500 | |
| Filed 2025-09-02 10:23 Tx date 2025-08-29 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
$87,500
+125,000 vol $0.70 each |
||
| Filed 2025-09-02 10:23 Tx date 2025-08-29 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
$87,500
+125,000 vol $0.70 each |
375,000 | |
| Filed 2025-09-02 10:20 Tx date 2025-08-29 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
11 - Acquisition or disposition carried out privately
|
$50,000
+125,000 vol $0.40 each |
375,000 | |
| Filed 2025-09-02 10:20 Tx date 2025-08-29 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
11 - Acquisition or disposition carried out privately
|
$50,000
+125,000 vol $0.40 each |
||
| Filed 2025-05-30 15:54 Tx date 2025-05-30 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
10 - Acquisition or disposition in the public market
|
$2,062
+5,500 vol $0.375 each |
25,000 | |
| Filed 2025-05-30 12:40 Tx date 2025-05-30 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
10 - Acquisition or disposition in the public market
|
$3,080
+8,000 vol $0.385 each |
19,500 | |
| Filed 2025-05-30 12:38 Tx date 2025-05-29 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
10 - Acquisition or disposition in the public market
|
$750.00
+2,000 vol $0.375 each |
11,500 | |
| Filed 2025-05-30 12:37 Tx date 2025-05-27 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
10 - Acquisition or disposition in the public market
|
$770.00
+2,000 vol $0.385 each |
9,500 | |
| Filed 2025-05-30 12:37 Tx date 2025-05-27 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
10 - Acquisition or disposition in the public market
|
$1,125
+3,000 vol $0.375 each |
7,500 | |
| Filed 2025-05-30 12:36 Tx date 2025-05-27 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
10 - Acquisition or disposition in the public market
|
$1,687
+4,500 vol $0.375 each |
4,500 | |
| Filed 2025-05-30 12:35 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-04-13 15:31 Tx date 2025-03-31 |
$LSL
LSL Pharma Group Inc. |
Laflamme, Louis
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
125,000 | ||
| Filed 2025-04-13 15:30 Tx date 2025-03-31 |
$LSL
LSL Pharma Group Inc. |
Laflamme, Louis
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
125,000 | ||
| Filed 2025-04-10 12:59 Tx date 2025-03-31 |
$LSL
LSL Pharma Group Inc. |
Laflamme, Louis
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|